Spotlight On... Sun Pharma shedding Ohio plant with sale to Nostrum Laboratories; Walgreens picking up Valeant biz; Workers killed at India plant; Zimbabwe restarting pharma production; and more...

India's Sun Pharmaceutical, looking to cut back its manufacturing operations since its buyout of Ranbaxy Laboratories, will sell a formulation plant in Bryan, OH, to Nostrum Laboratories. The companies are keeping terms of the deal under wraps. Sun had picked the plant up in 2005 from Valeant Pharmaceuticals ($VRX). It is the second plant that Sun has indicated it will dispose of. In September, the company said it was looking at closing a plant in Tipperary, Ireland, with 100 employees. Release | More

> Walgreens Boots Alliance ($WBA) has reportedly won a deal to distribute products for the troubled Valeant Pharmaceuticals ($VRX) through which Valeant is said to be cutting prices by 10%. Story

> CDMO Ajinomoto Althea next month will begin offering antibody-drug conjugate (ADC) services at a new facility near its existing San Diego, CA, operations. Release

> The government of Zimbabwe has taken over and plans to restart CAPS Holdings, which was the country's largest drug manufacturer before it collapsed four years ago. Story

> Three workers were killed and two are in critical condition after reportedly inhaling poisonous gas while working on a tank at Shree Ganesh Remedies Company in Ankleshwar, India. Story

> U.S.-based Hysun Biomedical is planning to shift its health supplements manufacturing to India. Report

Suggested Articles

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.